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Abstract
Chemotherapy has been the treatment of choice for unresectable peritoneal dissemination; however, it is difficult to eradicate such tumors because of poor drug delivery.
To solve this issue, we developed FF-10832 as liposome-encapsulated gemcitabine to maintain a high concentration of gemcitabine in peritoneal tumors from the circulation and ascites. A syngeneic mouse model of peritoneal dissemination using murine 
| INTRODUC TI ON
Peritoneal dissemination is a poor prognostic factor in several gastrointestinal and gynecological cancers. 1, 2 It is difficult to completely remove the peritoneal dissemination surgically; therefore, systemic chemotherapy has typically been performed for peritoneal dissemination. However, its therapeutic effect is insufficient at present owing to drug resistance as well as poor drug delivery to disseminated tumors from the circulation and ascites. 3, 4 Gemcitabine (2′,2′-difluoro-2′-deoxycytidine; dFdCyd) is a deoxycytidine analog that is incorporated into DNA, resulting in an anticancer effect via chain termination. 5 This drug is currently used as the standard chemotherapeutic agent for patients with malignant abdominal tumors that may cause unresectable peritoneal dissemination. [6] [7] [8] [9] However, it has been reported that gemcitabine can induce an interesting pharmacological effect not only on gemcitabine-treated cancer cells but also on the surrounding untreated cells. This unique transmission of therapeutic effect has been identified as the "bystander effect" of nucleoside analogs such as gemcitabine and ganciclovir. 10 From these observations, it has been suggested that maintaining a high gemcitabine concentration in the circulation and ascites that are in contact with disseminated tumors is important in curing peritoneal dissemination because effective gemcitabine delivery to a portion of the target tumors is expected to transmit the therapeutic effect to the entire population of disseminated tumor cells. However, gemcitabine has a rapid clearance from the circulation (half-life (t 1/2 ) = 0.3 hour), which may be a critical disadvantage in the eradication of peritoneal tumors because gemcitabine is known to be a time-dependent anti-tumor drug.
11 Therefore, improvement of the in vivo delivery and stability of gemcitabine is imperative for cancer patients with peritoneal dissemination.
Researchers have attempted several drug modifications to strengthen the enhanced permeability and retention (EPR) effect for effective drug delivery. For instance, various types of liposome-encapsulated anticancer drugs have shown significantly better effects against peritoneal dissemination via drug stability in the circulation due to an improvement in the EPR effect. [12] [13] [14] To solve the problem of the rapid clearance of gemcitabine, we developed FF-10832, as a liposome-encapsulated gemcitabine, to maintain a high drug concentration in the circulation and ascites that are in contact with the disseminated tumors.
The purpose of the present study was to evaluate the therapeutic efficacy of newly developed FF-10832, a liposome-encapsulated gemcitabine (Lipo-GEM), and to perform pharmacokinetic analysis to evaluate the EPR effect using a peritoneal dissemination mouse model. In the present study, we show a significant 
| Cell culture and animals
The luminescent mouse colorectal carcinoma cell line Colon26-luc (Colon26) was cultured in RPMI-1640 medium (Sigma Aldrich)
containing 10% FBS, 50 U/mL penicillin, 50 mg/mL streptomycin (Pen-strep; Gibco, Thermo Fisher Scientific) and 10 μg/mL puromycin (Sigma Aldrich) at 37°C in a humidified atmosphere with 5% CO 2 . Inbred female BALB ⁄cCrSlc mice (Japan SLC) were obtained at 5 weeks of age and maintained under specific pathogen-free conditions. These mice were used for experiments at 6 weeks of age. All experiments and procedures for care and treatment of the animals used in the present study were carried out in accordance with the requirements of the Gunma University Animal Care and Experimentation Committee (Experimental Protocol: No. 14-026;
Gunma University, Maebashi, Japan).
| Murine peritoneal dissemination model
Thirty mice were intraperitoneally inoculated with Colon26 cells
(1 × 10 6 cells in 0.5 mL PBS) (day 0). Mice were randomly divided into 3 groups on day 3 according to the intensity of luminescence, as described previously 15 : vehicle-treated group (n = 10), GEM-treated group (240 mg/kg Eli Lilly, n = 10) and FF-10832-treated group (3 mg/kg, Fujifilm, n = 10). In our lethal model mice, we had already validated the establishment of tumor inoculation on peritoneal cavity pathologically on day 5 after intraperitoneal injection (data not shown).These drugs were administered to the mice on day 5 by intravenous injection. Peritoneal dissemination was examined using an in vivo luciferase assay on days 3, 7, 12, 17, 22 and 29 following transplantation. We plotted body weight until day 22 following transplantation and Kaplan-Meier survival curves until day 56 following transplantation in each group. On day 56 following transplantation, surviving mice were killed to evaluate the peritoneal tumor conditions using an ex vivo luciferase assay, as previously described. 15 The peritoneal tumors in each group were observed using H&E staining.
The tumor samples were collected from moribund mice in the vehicle-treated and GEM-treated groups.
| Pharmacokinetic analysis
The time course of gemcitabine concentration was evaluated in the plasma and ascites of each group. The gemcitabine concentrations were measured in plasma and ascites following a single intravenous administration of 240 mg/kg GEM or 3 mg/kg FF-10832
to Colon26-bearing mice 7 days after intraperitoneal inoculation.
Both doses were decided as the maximum tolerated dose from our preliminary study. 16 For the plasma pharmacokinetics of gemcitabine, blood samples were collected in tubes containing 100 μg/ 
| H&E staining
Tissues were fixed in 10% neutral-buffered formalin (Wako), embedded in paraffin (Sakura Finetek Japan), and 2-μm sections were subsequently prepared. The sections were stained with H&E (Hematoxylin 3G, Sakura Finetek, Japan; Eosin, Wako, Japan) using standard procedures (hematoxylin, 1 minute; eosin, 1 minute). Snapshots of histology were taken using an Olympus BX51 microscope.
| Statistical analysis
Overall survival was measured from the day of Colon26 injection and plotted according to the Kaplan-Meier method; the log-rank test was used for comparisons. Concentrates of gemcitabine in tumor tissue were assessed using the Wilcoxon test. A P-value of ≤0.05
was defined as statistically significant. Statistical analyses were performed using the JMP software (SAS Institute).
| RE SULTS
| Characteristics of FF-10832 as a novel liposome-encapsulated gemcitabine
In the present study, we developed FF-10832, a liposome-encapsulated gemcitabine in the dissolved state using Figure 2B shows the gemcitabine concentration-time curves in ascites. In addition to an improvement in the t 1/2 in plasma, the t 1/2
value of FF-10832 in ascites was longer than that of GEM (GEM:
F I G U R E 2 Pharmacokinetic analysis of gemcitabine in Colon26 peritoneal dissemination model mice following a single administration of gemcitabine (GEM) or FF-10832. A, Gemcitabine (dFdCyd) concentration-time curves in plasma and pharmacokinetic parameters. Plasma samples were collected at various intervals. Each data represents the mean ± standard deviation (n = 3 or 4). B, Gemcitabine concentrationtime curves in ascites. Ascites samples were collected at various intervals. Each data represents the mean ± standard deviation (n = 3 or 4). C, Gemcitabine concentrations in the tumor 24 h following administration. Each data represents the mean ± standard deviation (n = 3). AUC0-last, area under the curve; AUC0-last/dose, dose-normalized area under the curve; CL, total clearance; t 1/2 , half-life; Vdss, volume of distribution at steady state t 1/2 = 2.32 hours; FF-10832: t 1/2 = 10.9 hours). Moreover, Figure 2C shows the gemcitabine concentration in peritoneal tumors 24 hours following administration of GEM or FF-10832. As a result, the intratumoral gemcitabine concentration in the FF-10832 group was significantly higher than that in the GEM group (P = 0.04). Figure 2A -C suggests that FF-10832 achieved a long circulatory time in plasma and ascites, which allowed successful delivery of gemcitabine to the disseminated tumors via liposome encapsulation.
| FF-10832 administration prolonged survival in the peritoneal dissemination mouse model
In the in vivo luciferase assay, luminescence was observed on day In the present study, we measured the body weight in each group ( Figure S1 ). After administration, the body weight in the GEM group was decreased by 5.2%, while that in FF-10832 was decreased by 2.5%. No other obvious side effects were observed in both groups. Body weight loss in the vehicle-treated group was observed on day 12 followed by initiation of death. In the GEMtreated group, a significant body weight loss was observed from day 12 due to progression of peritoneal disseminated tumors.
In contrast, continuous body weight gain was observed in the FF-10832-treated group until day 22. All mice in the FF-10832-treated group were alive during the measurement period of 22 days.
| FF-10832 administration strongly suppressed tumor growth in the peritoneal dissemination mouse model
The luminescence spots of disseminated tumors were strongly detected in the vehicle-treated group as compared with the GEM-treated group. In contrast, disseminated tumors in the FF-10832-treated group were undetectable as luminescence spots using a highly sensitive ex vivo luciferase assay that can diagnose the existence of invisible tumors ( Figure 4 ; upper panel). Interestingly, microscopy analysis clarified that viable disseminated tumor mass in the FF-10832-treated group was almost completely absent; however, evident tumor masses existed in the vehicle-treated and GEM-treated groups (Figure 4 ; bottom panel).
| D ISCUSS I ON
In the present study, we developed a novel liposome-encapsulated gemcitabine, FF-10832, with a significantly improved EPR effect and stability in the circulation and ascites. Moreover, a single adminis- In the present study, we focused on the liposome encapsulation of gemcitabine to improve anticancer drug delivery against peritoneal disseminated tumor cells, which cause death in patients with gastrointestinal and gynecological cancer. Intraperitoneal injection can achieve continuation of a high drug concentration in the peritoneal cavity as compared with systemic injection. 22 Armstrong et al, 23 report that intraperitoneal administration of cisplatin and paclitaxel improves prognosis in ovarian cancer patients with peritoneal dissemination as compared with intravenous systemic chemotherapy.
However, it is known that intraperitoneal injection has certain disadvantages, such as injury of abdominal organs and catheter-related complications, including obstruction, infection and catheter migration into the abdominal cavity. 
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